Merck

We aspire to be the premier research-intensive biopharmaceutical company. Intended for U.S. residents only.
FLS:

[Merck @Merck]

Today at #ASCO26, in collaboration with @moderna_tx, we're proud to present five-year follow-up results from a Phase 2b study evaluating our investigational individualized neoantigen therapy for #melanoma. Learn more: https://t.co/ArMtq1C10C

[Merck @Merck]

@AdrianaJeffery Hi Adriana. We're sorry to hear your frustration. Please contact our National Service Center at [email protected] or 1.800.672.6372 and they can do their best to address your concern.

[Merck @Merck]

The U.S. FDA has granted Breakthrough Therapy designation for one of our investigational pipeline candidates for certain patients with KRAS G12C mutant non-small cell #lungcancer (#NSCLC).

Learn more: https://t.co/U2KXHX4mOa

[Merck @Merck]

@joshua_rogers15 Hi Joshua, your safety and the safety of our products is important to us. We’d appreciate the opportunity to learn more about your experience. Please contact the National Service Center at [email protected] or call 1.800.672.6372.

[Merck @Merck]

Today the CHMP issued a positive opinion of a new treatment combination for certain patients with muscle-invasive #BladderCancer (MIBC). Together with Pfizer and Astellas Pharma, we’re committed to advancing new options to address unmet needs. Learn more: https://t.co/Iva8xEmmSj

[Merck @Merck]

Today, we announced the first positive Phase 3 results from our investigational TROP2-directed antibody-drug conjugate (ADC) in certain patients with advanced or recurrent endometrial cancer. This milestone represents the first results from our broad TroFuse clinical trial program and reflects our ongoing commitment to advancing research in women’s cancers.

Learn more here: https://t.co/tZB4sygcHb

[Merck @Merck]

We’re presenting new data at #ASCO26 from our robust oncology portfolio and pipeline across earlier-stage and advanced tumor types. We’re focused on advancing research to fight cancer and evaluate new approaches to help prolong and protect lives. Learn more: https://t.co/9JsjsCmvHk

[Merck @Merck]

Every day, our scientists tackle challenging problems like the scalable synthesis of complex molecules. In this latest publication in @ScienceMagazine, we share how we’re using #biocatalysis to manufacture orally available macrocyclic peptides. Learn more: https://t.co/iH0ZOd50vV

[Merck @Merck]

Today, Merck completed the acquisition of Terns Pharmaceuticals, further strengthening our #oncology portfolio and reinforcing our focus on science‑driven innovation. Learn more: https://t.co/WeGG2NeJRt

[Merck @Merck]

Join us today at 9 a.m. ET to learn more about our Q1 2026 #earnings: https://t.co/J4mdU2WLgv $MRK

[Merck @Merck]

Our Q1 2026 #earnings results are live. Check out our full $MRK financial summary and key highlights: https://t.co/8MwIHBdFhE

[Merck @Merck]

Now that baseball season has returned to ballparks across the country, we’re proud to team up with @WomenHeartOrg & 9 professional baseball teams to help shine a spotlight on bad cholesterol & the risk of heart attack or stroke. Learn more about Playing with Heart: https://t.co/7DOKXcUjdl

[Merck @Merck]

We’re proud to partner with @googlecloud to help shape the future of biopharmaceutical innovation with AI-enabled enterprise transformation.

This collaboration is about unlocking new value: accelerating discovery, modernizing how we work and empowering our teams to focus on the highest-impact science and solutions for patients.

Learn more about the landmark partnership: https://t.co/B67DdKSb8U

[Merck @Merck]

There’s a new treatment option for certain adults living with HIV. Learn more here: https://t.co/inb1LZ1XTL

[Merck @Merck]

Learn more about our latest update in #oncology: https://t.co/XXEBUXioBg

[Merck @Merck]

The FDA accepted our application for a perioperative treatment for #BladderCancer, which affects 84,000+ people in the U.S. each year. With @pfizer and @AstellasUS , we’re committed to advancing care and addressing recurrence in muscle-invasive disease. Learn more: https://t.co/PDKCZN8f7Q

[Merck @Merck]

Today, we’re proud to announce the European Commission’s approval of an option to help protect infants against respiratory syncytial virus (#RSV). Learn more: https://t.co/BxUuHzGrrU

[Merck @Merck]

@karriehiggins Hi, we're sorry to hear your frustration. Please contact our National Service Center at [email protected] or 1.800.672.6372 and they can do their best to address your concern.

[Merck @Merck]

Today, in collaboration with @DaiichiSankyoUS, we are proud to announce that the #FDA has granted Priority Review for a new treatment option for certain patients with extensive-stage small cell lung #cancer. Learn more here: https://t.co/jq7EMxRjVY

[Merck @Merck]

Today we announced the initiation of a pivotal Phase 2b/3 trial for the treatment of patients with neovascular age-related macular degeneration (#wetAMD). Learn more: https://t.co/vr9aWBmMlz #ophthalmology